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ABSTRACT
Human dopamine D2 and D3 receptors were expressed in
Chinese hamster ovary (CHO) and Escherichia coli cells to
compare their ligand binding properties in the presence or
absence of G-proteins and to analyze their ability to interact
with Gi/o-proteins. Binding affinities of agonists (dopamine,
7-OH-DPAT, PD128907, lisuride) and antagonists/inverse ago-
nists (haloperidol, risperidone, domperidone, spiperone, raclo-
pride, nemonapride), measured using [125I]iodosulpride and
[3H]7-OH-DPAT, were similar for hD3 receptors in E. coli and
CHO cell membranes. Both agonists and antagonists showed
2- to 25-fold lower binding affinities at hD2 receptors in E. coli
versus CHO cell membranes (measured with [3H]spiperone),
but the rank order of potencies remained similar. Purported
inverse agonists did not display higher affinities for G-protein-
free receptors. In CHO membranes, GppNHp decreased high
affinity agonist ([3H]7-OH-DPAT) binding at hD2 receptors but
not at hD3 receptors. Also, [
3H]7-OH-DPAT (nanomolar con-
centration range) binding was undetectable at hD2 but clearly
measurable at hD3 receptors in E. coli membranes. Addition of
a Gi/o-protein mix to E. coli membranes increased high affinity
[3H]7-OH-DPAT binding in a concentration-dependent manner
at hD2 and hD3 receptors; this effect was reversed by addition
of GppNHp. The potency of the Gi/o-protein mix to reconstitute
high affinity binding was similar for hD2 and hD3 receptors.
Thus, agonist binding to D3 receptors is only slightly affected by
G-protein uncoupling, pointing to a rigid receptor structure.
Furthermore, we propose that the generally reported lower
signaling capacity of D3 receptors (versus D2 receptors) is not
due to its lower affinity for G-proteins but attributed to its lower
capacity to activate these G-proteins.
Dopamine receptors belong to the superfamily of G-pro-
tein-coupled receptors. Five dopamine receptors have been
found and classified into the D1-like family (D1 and D5 re-
ceptors) and the D2-like family (D2, D3, and D4 receptors)
(Missale et al., 1998). Receptor genes of the D1-like family do
not contain introns, whereas members of the D2-like family
possess multiple introns. For instance, two splice variants of
the D2 receptor have been found; the D2short (D2S) receptor,
lacking a 29-amino acid insert in the third cytoplasmic loop,
and the D2long (D2L) receptor (Monsma et al., 1989). Differ-
ences in G-protein coupling of these splice variants have been
reported (Picetti et al., 1997), but the physiological relevance
of these splice variants remains unclear.
Human dopamine D2 and D3 receptors have an overall
amino acid sequence similarity of 52%, which increases to
78% if only transmembrane regions are considered (Giros et
al., 1990). Most ligands that bind to hD2 receptors also bind
to hD3 receptors and their rank order of potency is quite
similar. In general, dopamine agonists have a higher affinity
for hD3 receptors, whereas antagonists have a slightly higher
affinity for hD2 receptors. The pharmacological properties of
the hD2 receptor splice variants are almost identical (Liu et
al., 1992; Leysen et al., 1993; Schotte et al., 1996). Although
both hD2 and hD3 receptors are thought to couple to Gi/o
proteins, this is much less clear for the hD3 than for the hD2
receptor. Guanine nucleotide modulation of agonist binding
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at hD2 receptors has been clearly demonstrated, whereas
conflicting results have been obtained for hD3 receptors
(Sokoloff et al., 1992; Freedman et al., 1994; MacKenzie et
al., 1994; Tang et al., 1994; Akunne et al., 1995; McAllister et
al., 1995). In addition, coupling of hD2 receptors to various
pertussis-toxin-sensitive signaling pathways has been re-
ported, whereas a total lack or a weak coupling to these
pathways has been described for hD3 receptors (MacKenzie
et al., 1994; Tang et al., 1994; McAllister et al., 1995). Only
recently, we succeeded in demonstrating clear activation of
hD3 receptors at different levels of the signal transduction
cascade when expressed at high levels in Chinese hamster
ovary (CHO) cells (Vanhauwe et al., 1999).
According to the allosteric ternary complex model (Lefkow-
itz et al., 1993; Samama et al., 1993), receptors, by them-
selves, can occur in an active and an inactive state. In the
absence of agonist, a fraction of the receptor population can
exist in an active state, leading to basal or constitutive ac-
tivity. Agonist binding increases the population of active
receptors. In contrast, binding of inverse agonists drives the
receptor to the inactive state, diminishing the basal activity.
It is not yet clear whether agonist binding recruits G-proteins
to the activated receptor or that G-protein coupling promotes
subsequent agonist binding. Probably, both processes play in
concert (ternary complex formation). However, it is generally
found that agonists bind with higher affinity to G-protein-
coupled receptors than to uncoupled receptors, whereas neu-
tral antagonists do not distinguish between G-protein-cou-
pled and uncoupled receptors. Furthermore, it was suggested
that inverse agonists have a higher affinity for uncoupled
than for G-protein-coupled receptors (Costa et al., 1992).
Inverse agonists have been identified for D2 (Hall and
Strange, 1997; Kozell and Neve, 1997; Vanhauwe et al., 2000)
and D3 receptors (Griffon et al., 1996; Malmberg et al., 1998),
indicating that both receptors can have basal activity.
To demonstrate clearly the effect of G-protein receptor
coupling on ligand binding, one would need the receptor in a
G-protein-free environment. Escherichia coli cells, which do
not contain G-proteins, provide a system for producing un-
coupled receptors. Certain G-protein-coupled receptors have
been successfully expressed in E. coli (Marullo et al., 1990;
Freissmuth et al., 1991; Bertin et al., 1992; Grisshammer et
al., 1993; Munch et al., 1995).
In this study, we succeeded for the first time to express
hD2S, hD2L, and hD3 receptors in E. coli. To scrutinize the
difference in G-protein-coupling properties of hD2S, hD2L,
and hD3 receptors, we compared the binding properties of
agonists and antagonists for recombinant receptors ex-
pressed in E. coli versus CHO cells. Measurements on recom-
binant hD2 and hD3 receptors in E. coli membranes were
carried out in the absence or presence of added Gi/o-proteins.
Our study illustrates that agonist binding to hD3 receptors is
poorly sensitive to G-protein coupling, whereas hD2 receptor
high affinity agonist binding is highly dependent on G-pro-
teins. Nevertheless, hD3 and hD2 receptors were found to
have equal affinity for the Gi/o-protein mix. A constrained
hD3 receptor structure that retains a conformation of high
affinity agonist binding in the uncoupled and G-protein state
is hypothesized, along with a conformation that binds well,
but poorly activates G-proteins.
Experimental Procedures
Bacterial Expression and Membrane Preparation. The
cDNAs of hD2S, hD2L, and hD3 receptors were cloned, and the se-
quence was verified by DNA sequencing (Schotte et al., 1996). For
each receptor, the cDNA was ligated in the expression vector pMal-p
so that it was in-frame with the maltose binding protein (MalE). All
plasmid constructs were confirmed by DNA sequencing. The result-
ing plasmids coded for the MalE protein fused via a polylinker,
containing a protease factor Xa cleavage site, to the receptor at the C
terminus. Fusion and wild-type plasmids were transformed into
competent E. coli TB1 cells [araD (lac proAB) rpsL (F80 lacZDM15)
hsdR] by electroporation and plated on 2xYT plates containing 100
mg/ml ampicillin. A single colony was inoculated into 2 ml of 2xYT
medium containing 100 mg/ml ampicillin. After 8 h of growth, the
2-ml starter culture was added to 500-ml 2xYT medium containing
100 mg/ml ampicillin and grown overnight in a shaking incubator
(New Brunswick Scientific, Edison, NJ) at 300 rpm and 37°C. The
optical density was determined, and the cells were harvested by
centrifugation (2000g for 10 min at 4°C) and resuspended to an
optical density of 1.5 in 2xYT, containing 100 mg/ml ampicillin and
0.5 mM isopropyl-b-D-thiogalactopyranoside. Cells were further in-
cubated for 4 h at 25°C, harvested by centrifugation, and resus-
pended in ice-cold 50 mM Tris-HCl, pH 7.4, containing 20% sucrose
and 1 freshly dissolved tablet of protease inhibitor cocktail (Com-
plete) per 50 ml. In a first series of experiments on the pharmaco-
logical characterization of hD3 receptors, E. coli cell suspensions
were frozen as pellets and thawed before use. In subsequent studies
on the characterization of D2 receptors and addition of G-proteins to
E. coli membranes, frozen droplets were prepared by freezing drops
of the cell suspension in liquid nitrogen followed by storage at 270°C
until use. After thawing of the droplets, the cell suspension was
passed four times at 800 psi through a French press (Spectronic
Instruments, Cheshire, England). The suspension was diluted in 50
mM Tris-HCl, pH 7.4, containing 10% glycerol. After a low spin
centrifugation (1400g for 5 min at 4°C) for removal of intact cells, the
supernatant was collected and centrifuged at 90,000g for 1 h at 4°C.
The membrane pellet was suspended in 50 mM Tris-HCl, pH 7.4,
containing 10% glycerol and used in radioligand binding experi-
ments.
CHO Cell Culture and Membrane Preparation. CHO cells
expressing the hD2S, hD2L, or D3 receptors (Vanhauwe et al., 1999)
were grown in Dulbecco’s modified Eagle’s medium supplemented
with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin,
100 mg/ml streptomycin, and 10% fetal calf serum in a humidified
atmosphere of 5% CO2 at 37°C. Cells were subcultured at 80 to 90%
confluence.
Cells were subcultured from 175-cm2 tissue culture flasks to 145-
cm2 Petri dishes. At 90% confluence, 5 mM sodium butyrate was
added to increase the receptor expression level and the cells were
further incubated for 24 h (Palermo et al., 1991). The medium was
removed, and the Petri dishes were washed once with 5 ml of ice-cold
PBS and stored at 270°C. Cells on Petri dishes were thawed, and 5
ml of 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM 4-(2-amino-
ethyl)benzenesulfonylfluoride hydrochloride was added per dish.
The cells were harvested and homogenized with a dual homogenizer
(motor-driven Teflon pestle and conical glass tube). The homogenate
was centrifuged (10 min at 1000g at 4°C), and the resulting pellet
was resuspended and centrifuged again (10 min at 1300g at 4°C).
Both supernatants were pooled and centrifuged at 50,000g for 1 h at
4°C. The resulting pellet was resuspended in 50 mM Tris-HCl (pH
7.4), containing 10% glycerol and stored in aliquots at 270°C. The
protein concentration in membrane preparations was measured with
the Bradford protein assay using BSA as a calibration standard.
Radioligand Binding Assays. For radioligand binding experi-
ments on hD3R-E. coli cells, the cell suspension was thawed and
washed twice in the incubation buffer for the ligand. For radioligand
binding experiments on E. coli or CHO cell membranes, the mem-
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branes were thawed and resuspended in the incubation buffer for the
ligand.
[3H]7-OH-DPAT was used to measure agonist binding to hD3,
hD2S, and hD2L receptors. The incubation with [
3H]7-OH-DPAT was
performed for 30 min at 25°C in a total volume of 0.5 ml, containing
50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, and 1 mM EGTA (for
hD2R-E. coli membranes, the total incubation volume was 1 ml).
[125I]Iodosulpride was used to measure antagonist binding to hD3
receptors in E. coli cells and CHO cell membranes. The incubation
with [125I]iodosulpride was performed for 30 min at 25°C in a total
volume of 0.25 ml, containing 50 mM Tris-HCl, pH 7.4, 120 mM
NaCl, and 0.1% BSA. [3H]Spiperone was used to measure antagonist
binding to hD2S and hD2L receptors in E. coli membranes and CHO
cell membranes. The incubation with [3H]spiperone was performed
for 30 min at 37°C in a total volume of 0.5 ml, containing 50 mM
Tris-HCl, pH 7.4, and 120 mM NaCl (for hD2R-E. coli membranes the
total incubation volume was 1 ml). The amount of protein per incu-
bation was 10 to 20 mg for E. coli membranes and cells and for
hD2SR-CHO cell membranes. For hD3R-CHO and hD2LR-CHO cell
membranes 5 to 10 mg of protein was used. Nonspecific binding was
estimated in the presence of 10 mM haloperidol. The reaction was
terminated by filtration through Whatman GF/B filters, presoaked
in 0.1% polyethyleneimine. Filters were rinsed twice with 5 ml of
ice-cold incubation buffer. The filter-bound radioactivity was mea-
sured in a liquid scintillation spectrometer (Tricarb, Packard, Meri-
den, CT), using 3 ml of scintillation fluid. Specific binding was
calculated as the difference between total binding and nonspecific
binding. For ligand concentration binding isotherms, [3H]7-OH-
DPAT was used at 10 to 12 concentrations in the range of 0.1 to 20
nM for CHO cell membranes and 0.1 to 10 nM for E. coli cell
membranes (high concentrations of [3H]7-OH-DPAT resulted in high
nonspecific binding at E. coli membranes), and [125I]iodosulpride was
used at 10 concentrations in the range of 0.1 to 3 nM and [3H]spip-
erone was used at 10 to 12 concentrations in the range of 0.01 to 1
nM.
Ligand concentration binding isotherms were fitted to a rectangu-
lar hyperbola by nonlinear regression analysis in which the apparent
equilibrium dissociation constant (Kd) and the maximum number of
binding sites (Bmax) were free parameters. Computerized curve fit-
ting was performed using the GraphPad Prism software.
In competition binding experiments at hD3 receptors, serial dilu-
tions of unlabeled compounds were incubated with [3H]7-OH-DPAT
(2 nM) or [125I]iodosulpride (0.4 nM) and CHO or E. coli membranes.
In the case of hD2S and hD2L receptors, serial dilutions of unlabeled
compounds (10–12 concentrations, range 0.1 mM to 0.1 nM) were
incubated with [3H]spiperone (0.5 nM) and CHO or E. coli mem-
branes. Competition curves were fit to a sigmoid by nonlinear re-
gression analysis according to algorithms described by Oestreicher
and Pinto (1987), in which the pIC50 and the Hill coefficient were free
parameters. Inhibition constants (Ki) were calculated according to
Cheng and Prusoff (1973). Assays were run in duplicate in ligand
concentration binding isotherms and in singlets in competition bind-
ing experiments and repeated in independent experiments (n num-
bers in tables and figures). Curves were calculated for individual
experiments, and the mean of the derived parameters was calcu-
lated.
Reconstitution of High Affinity [3H]7-OH-DPAT Binding
with G-Proteins. A commercially available bovine Gi/o-protein mix
(Gai1, Gai2, Gai3, Gao, Gbg purified from bovine brain) was diluted in
50 mM Tris-HCl, pH 7.4, containing 10 mM MgCl2, 1 mM EGTA, and
0.15% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic
acid (CHAPS) and then 5-fold diluted and mixed with E. coli mem-
brane suspension by vortexing. At this concentration of CHAPS, 90%
of the binding is retained (results not shown). E. coli membranes
(30–40 mg of protein/300 ml) were incubated in a total volume of 0.5
ml with serial dilutions of the G-protein mix and 0.75 nM or 2 nM
[3H]7-OH-DPAT for hD3 and hD2S receptors, respectively. The assay
buffer contained 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 1 mM
EGTA, and 0.03% CHAPS. After a 30-min incubation period at 25°C,
the reaction was terminated by filtration and the amount of bound
radioactivity was determined as described above. The concentration
of the Gi/o-protein mix was calculated assuming an average molecu-
lar mass of 87,000 Da.
Materials. [3H]Spiperone (3.5 TBq/mmol), [125I]iodosulpride (74.1
TBq/mmol), and [3H]7-OH-DPAT (5.5 TBq/mmol) were purchased
from Amersham Pharmacia Biotech (Little Chalfont, UK). The E.
coli strain (TB1) was from Stratagene (La Jolla, CA). The expression
vector pMal-p was purchased from New England BioLabs (Leusden,
Netherlands). The Gi/o-protein mix purified from bovine brain was
obtained from Calbiochem (La Jolla, CA).
The 2xYT, Dulbecco’s modified Eagle’s medium, and fetal bovine
serum were from Life Technologies (Gaithersburg, MD). The Brad-
ford protein assay kit was from Bio-Rad (Richmond, CA). PD128907
and dopamine were purchased from Research Biochemicals Interna-
tional (Natick, MA). Raclopride and nemonapride were from Astra
Arcus (Stockholm, Sweden) and Yamanouchi (Tokyo, Japan), respec-
tively. TL99 was from ICN Pharmaceuticals (Costa Mesa, CA). Hal-
operidol, domperidone, risperidone, and spiperone are original prod-
ucts of Janssen Pharmaceutica (Beerse, Belgium). 7-OH-DPAT
(racemic mixture) was synthesized in-house. Ampicillin, Complete
protease inhibitor cocktail, CHAPS, isopropyl-b-D-thiogalactopyr-
anoside, and 4-(2-aminoethyl)benzenesulfonylfluoride hydrochloride
were purchased from Boehringer Mannheim (Mannheim, Germany).
All other reagents were analytical grade from Merck (Haasrode,
Belgium) or Sigma (St. Louis, MO). GF/B glass-fiber filters were from
Whatman (Kent, UK). The scintillation fluid (Ultima Gold MV) was
from Packard (Meriden, CT). The GraphPad Prism program was
from GraphPad Software, Inc. (San Diego, CA). Dopamine, 7-OH-
DPAT, and PD128907 were dissolved and diluted in assay buffer.
Lisuride and TL99 were dissolved and diluted in ethanol. Haloperi-
dol, spiperone, domperidone, risperidone, raclopride, and
nemonapride were dissolved and diluted in dimethyl sulfoxide
(DMSO). For compounds that were dissolved and diluted in DMSO or
ethanol, a last dilution step of 20-fold in assay buffer was performed
just before addition to the assay mixture in which the dilution was
10-fold. In control assays, ethanol or DMSO was added to a final
concentration of 0.5%.
Results
Ligand Concentration Binding Isotherms at hD3 Re-
ceptors. Ligand concentration binding isotherms on hD3
receptors were measured with the partial agonist [3H]7-OH-
DPAT and the antagonist [125I]iodosulpride on E. coli cells
and CHO cell membranes expressing the recombinant recep-
tor (Vanhauwe et al., 1999). The ligand concentration bind-
ing curve of [125I]iodosulpride on E. coli cells is shown in Fig.
1A. Bmax and apparent Kd values obtained with hD3R-E. coli
cells and hD3R-CHO cell membranes are shown in Table 1A.
The affinity of [125I]iodosulpride for hD3 receptors expressed
in E. coli or CHO cells was similar (Kd 5 1.2–1.4 nM). Also,
the agonist [3H]7-OH-DPAT bound with comparable affinity
to hD3R-E. coli cells and hD3R-CHO cell membranes (Kd 5
1.5 nM). The affinity of [3H]7-OH-DPAT for hD3R-CHO cell
membranes was not affected by addition of GppNHp. No
binding could be detected in vector-transformed E. coli cells
and CHO cell membranes with either radioligand.
Ligand Concentration Binding Isotherms for hD2S
and hD2L Receptors. Ligand concentration binding iso-
therms on hD2 receptors were measured with the partial
agonist [3H]7-OH-DPAT and the antagonist [3H]spiperone.
To improve the signal-to-noise ratio, membranes were pre-
pared from E. coli cells expressing hD2S or hD2L receptors.
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The ligand concentration binding curves of [3H]spiperone on
hD2SR- and hD2LR-E. coli membranes are shown in Fig. 1, B
and C, respectively. Bmax and apparent Kd values are listed
in Table 1B. The antagonist [3H]spiperone bound with a
similar affinity to hD2S and hD2L receptors in E. coli than in
CHO cell membranes (Student’s t test, P . .05; Kd 5 0.1–0.2
nM)). [3H]7-OH-DPAT binding was undetectable in hD2SR-E.
coli or hD2LR-E. coli cell membranes within the tested con-
centration range (0.1–10 nM). In contrast, [3H]7-OH-DPAT
bound to hD2SR- and hD2LR-CHO cell membranes; its affin-
ity was similar for either splice variant (Kd 5 2.3–2.9 nM).
Addition of GppNHp significantly decreased by nearly 4-fold
the affinity of [3H]7-OH-DPAT for hD2S (Student’s t test, P ,
.005) and hD2L (Student’s t test, P , .05) receptors in CHO
cell membranes.
Inhibition Binding Experiments at hD3 Receptors.
The agonists dopamine, 7-OH-DPAT, PD128907, TL99, and
lisuride and the presumed antagonists haloperidol, spiper-
one, domperidone, risperidone, raclopride, and nemonapride
were tested for their potency to inhibit [125I]iodosulpride and
[3H]7-OH-DPAT binding to hD3 receptors. The pIC50 and Ki
values are listed in Table 2. In general, the apparent binding
affinities of the antagonists for hD3 receptors expressed in E.
coli versus CHO cells were similar when using [125I]iodosul-
pride or [3H]7-OH-DPAT. The apparent affinities of agonists
were comparable for hD3 receptors expressed in E. coli or
CHO cells, when tested with [125I]iodosulpride. When [3H]7-
OH-DPAT was used, dopamine and 7-OH-DPAT were signif-
icantly (5–7-fold) less potent at E. coli than at CHO cell
membranes (paired Student’s t test, P , .05); no significant
decrease in potency could be found for PD128907, TL99, and
lisuride in E. coli cells (paired Student’s t test, P . .05). The
rank order of potencies of agonists and antagonists was quite
similar in hD3R-E. coli and hD3R-CHO cell membranes. In
hD3R-E. coli cells and CHO membranes, raclopride and
nemonapride showed lower apparent binding affinities with
[3H]7-OH-DPAT than with [125I]iodosulpride. It should be
noted that both compounds are benzamides like [125I]iodosul-
pride; close structural similarities between nonlabeled and
labeled ligands often leads to more effective inhibition.
Inhibition Binding Experiments at hD2S and hD2L
Receptors. The same series of agonists and antagonists
were tested for their potency to inhibit [3H]spiperone bind-
ing; pIC50 and Ki values are listed in Table 3. The rank order
of antagonist potencies was similar for hD2S and hD2L recep-
tors when expressed in E. coli or CHO cell membranes. The
apparent binding affinities of antagonists for hD2L receptors
in E. coli membranes were two to five times lower than those
in CHO cell membranes. Some compounds showed higher
differences with the hD2S receptor. Dopamine and 7-OH-
DPAT were about 10 to 20 times less potent in E. coli mem-
branes than in CHO cell membranes; PD128907 and lisuride
were only three times less potent at hD2-E. coli than at
hD2-CHO cell membranes. In CHO cell membranes, the po-
tencies of compounds at hD2S and hD2L receptors were vir-
tually similar. This was also the case for these splice variants
when expressed in E. coli (except for raclopride).
Reconstitution of G-Protein Interaction with hD2S
and hD3 Receptors in E. coli. In a first series of experi-
ments (see Fig. 2), radioligand binding isotherms were deter-
Fig. 1. Antagonist radioligand binding isotherms using [125I]iodosulpride at hD3-E. coli cells (A) and [
3H]spiperone at hD2S-E. coli (B) or hD2L-E. coli
(C) cell membranes. Experiments are performed as described under Experimental Procedures. Representative curves are shown in which each point
was determined in duplicate. Mean Kd and Bmax values of three to six experiments are shown in Table 1.











































































































































































































































































































































































































































































































































































































































































































































































































































































































278 Vanhauwe et al. Vol. 295
mined with [3H]7-OH-DPAT using a fixed concentration
(62.3 nM) of the G-protein mix, which corresponds to a
G-protein/receptor ratio as indicated in Fig. 3. To compare
the agonist binding properties of hD2 and hD3 receptors, we
have prepared membranes from E. coli cells and incubated
them with the G-protein mix. The apparent affinity of [3H]7-
OH-DPAT for hD3 receptors in prepared membranes was
virtually equal to that in hD3R-E. coli cells, indicating that
preparation of the membranes does not alter the binding
properties of the receptor. [3H]7-OH-DPAT had an apparent
binding affinity of 1.7 6 0.2 nM (n 5 4) for untreated (Bmax
5 2000 6 300 fmol/mg of protein) and 1.1 6 0.2 nM (n 5 4)
for G-protein-treated hD3R-E. coli membranes (Bmax 5
2200 6 300 fmol/mg of protein); addition of GppNHp along
with the G-protein mix, resulted in an apparent binding
affinity of 2.0 6 0.3 nM (n 5 4) (Bmax 5 2200 6 200 fmol/mg
of protein). As mentioned before, [3H]7-OH-DPAT binding at
hD2R-E. coli membranes could not be determined in the
absence of G-proteins. However, when the G-protein mix was
added to the membranes, [3H]7-OH-DPAT binding was
clearly detectable at hD2SR-E. coli membranes (see Fig. 2)
with an apparent binding affinity of 3.5 6 0.1 nM (n 5 2)
(Bmax 5 160 6 30 fmol/mg of protein); addition of GppNHp
thereupon abolished [3H]7-OH-DPAT binding. At hD2LR-E.
coli membranes, [3H]7-OH-DPAT binding became apparent
on addition of G-proteins, but the signal-to-noise ratio was
too low for further characterization.
To determine the affinity of the G-protein mixture for hD2S
and hD3 receptors, we added increasing amounts of the G-
protein mixture to hD2SR- or hD3R-E. coli membranes and
measured the increase in [3H]7-OH-DPAT binding, which
was used at a concentration slightly lower than its deter-
mined apparent binding affinity in CHO cell membranes (i.e.,
0.75 nM for hD3 receptors and 2 nM for hD2S receptors).
Addition of Gi/o-proteins increased [
3H]7-OH-DPAT binding
to hD2SR and hD3R-E. coli membranes in a concentration-
dependent way (Fig. 3). The slopes of these curves were near
unity. Derived pEC50 values were 8.35 6 0.06 (n 5 4) for
hD3R-E. coli and 8.12 6 0.06 (n 5 4) for hD2SR-E. coli.
Apparently, the affinity of the Gi/o-protein mix for both re-
TABLE 2
Binding affinities (pIC50 mean 6 S.D. and apparent Ki value, n) of agonists and antagonists at hD3 receptors in E. coli cells and CHO cell
membranes, derived from competition binding experiments using 0.4 nM [125I]iodosulpride or 2 nM [3H]7-OH-DPAT at 25°C
Significant differences are indicated in superscript and explained below the table.
[125I]Iodosulpride [3H]7-OH-DPAT
CHO E. coli CHO E. coli
pIC50 Ki n pIC50 Ki n pIC50 Ki n pIC50 Ki n
2logM nM 2logM nM 2logM nM 2logM nM
Agonists
Dopamine 6.65 6 0.20 170 6 6.53 6 0.25 220 3 7.54 6 0.06 10.7 3 6.80 6 0.23 70.7a 6
TL99 7.90 6 0.02 9.8 3 7.98 6 0.22 7.9 6 8.78 6 0.09 0.63 3 8.67 6 0.22 1.1 4
PD128907 8.04 6 0.02 7.1 4 7.83 6 0.11 11.1 3 7.94 6 0.09 4.3 4 7.48 6 0.35 14.8 3
7OH-DPAT 8.28 6 0.19 4.1 4 8.15 6 0.24 5.3 5 8.38 6 0.10 1.6 3 7.79 6 0.26 7.2a 6
Lisuride 8.98 6 0.27 0.81 4 9.45 6 0.26 0.27 5 9.45 6 0.11 0.13 5 9.67 6 0.24 0.1 3
Antagonists
Haloperidol 7.60 6 0.19 19.4 4 7.30 6 0.30 37.2 5 8.02 6 0.20 3.6 4 7.21 6 0.32 27.7 6
Domperidone 7.60 6 0.20 19.4 3 7.51 6 0.20 23.3 4 7.49 6 0.18 12.1 4 7.18 6 0.28 29.1 5
Risperidone 7.86 6 0.29 10.9 6 8.01 6 0.22 7.4 5 7.70 6 0.16 7.4 3 7.68 6 0.35 9.3 4
Raclopride 8.45 6 0.09 2.8b 5 8.51 6 0.18 2.3b 4 6.84 6 0.25 53 5 6.49 6 0.26 150 6
Spiperone 8.90 6 0.07 0.98 5 8.73 6 0.32 1.4 6 9.07 6 0.18 0.32 5 8.61 6 0.23 1.1 6
Nemonapride 9.31 6 0.18 0.38b 5 9.57 6 0.29 0.2b 4 8.50 6 0.29 1.2 4 8.56 6 0.15 1.2 5
a The affinity of the compound for hD3 receptors was significantly lower in E. coli than in CHO membranes (P , .05).
b The affinity of the compound was significantly lower when tested with [3H]7-OH-DPAT (versus [125I]iodosulpride) (P , .05).
TABLE 3
Binding affinities (pIC50 mean 6 S.D. and apparent Ki value, n) of agonists and antagonists at hD2S and hD2L receptors in E. coli membranes and
CHO cell membranes, derived from competition binding experiments using 0.5 nM [3H]spiperone
hD2S Receptor hD2L Receptor
CHO E. coli CHO E. coli
pIC50 Ki n pIC50 Ki n pIC50 Ki n pIC50 Ki n
2logM nM 2logM nM 2logM nM 2logM nM
Agonists
PD128907 4.59 6 0.13 3900 3 4.39 6 0.05 11600 3 4.46 6 0.24 6000 3 4.30 6 0.13 7600 3
7OH-DPAT 5.19 6 0.22 1000 3 4.50 6 0.15 9100a 3 5.14 6 0.03 900 3 4.20 6 0.25 18000a 3
Dopamine 5.60 6 0.19 400 5 4.46 6 0.25 9800a 6 5.58 6 0.18 400 5 4.60 6 0.18 7200a 5
Lisuride 7.96 6 0.26 1.7 3 7.69 6 0.24 5.8 3 8.11 6 0.20 1.4 3 7.81 6 0.23 4.4 3
Antagonists
Raclopride 7.55 6 0.28 4.4 4 6.41 6 0.08 110a 3 7.49 6 0.12 4.9 4 6.22 6 0.18 170a 3
Risperidone 7.87 6 0.16 2.3 3 7.53 6 0.16 8.4 4 7.76 6 0.16 2.7 4 7.47 6 0.23 9.8 4
Nemonapride 8.36 6 0.23 0.67 3 8.09 6 0.29 1.3 4 8.44 6 0.23 0.55 4 8.28 6 0.29 0.8 4
Domperidone 8.57 6 0.20 0.41 3 7.74 6 0.19 5.2a 4 8.23 6 0.30 1 4 7.94 6 0.13 3.3 4
Haloperidol 8.58 6 0.20 0.41 4 7.60 6 0.14 7.2a 4 8.42 6 0.11 0.58 4 7.96 6 0.22 3.2a 4
Spiperone 9.07 6 0.05 0.13 3 9.01 6 0.10 0.28 4 9.13 6 0.14 0.1 4 9.05 6 0.26 0.26 3
a The affinity of the compound for hD2S/L receptors was significantly lower in E. coli than in CHO membranes (P , .05).
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ceptors was quite similar for hD3 than for hD2S receptors
(Student’s t test, P , .05). Indeed, assuming a bimolecular
interaction between the receptor and the heterotrimeric G-
protein, we estimated apparent dissociation binding con-
stants of 1.4 3 1027 M in hD3R-E. coli membranes and 9.4 3
1028 M in hD2SR-E. coli membranes (for details of calcula-
tion see Fig. 3). Addition of the Gi/o-protein mix to hD2SR-E.
coli or hD3R-E. coli membranes had no effect on antagonist
binding (results not shown). At the highest concentration of
the Gi/o-protein mix, we estimated a G-protein/receptor ratio
of 260 for hD3 and of 780 for hD2S receptors.
Discussion
We have used an E. coli and CHO expression system to
investigate the ligand binding properties of hD2S, hD2L, and
hD3 receptors in the absence or presence of G-proteins, re-
spectively. The goal was to obtain information on their re-
ceptor-G-protein interaction.
Successful Expression of hD2S, hD2L, and hD3 Recep-
tors in E. coli. We have demonstrated expression of hD2S,
hD2L, and hD3 receptors in E. coli membranes. The antago-
nist [125I]iodosulpride and partial agonist [3H]7-OH-DPAT
bound with similar affinity to hD3 receptors expressed in E.
coli and CHO cells (Table 1). In general, the apparent binding
affinities and the rank order of potency of the antagonists
and agonists tested were similar in hD3R-E. coli cells and
hD3R-CHO cell membranes (Table 2). [
3H]Spiperone bound
to hD2SR-E. coli and hD2LR-E. coli cell membranes with an
apparent affinity comparable with hD2SR-CHO and hD2LR-
CHO cell membranes (Table 1). The tested antagonists re-
vealed apparent affinities at hD2SR-E. coli and hD2LR-E. coli
membranes that were lower than their apparent affinities in
hD2SR-CHO and hD2LR-CHO cell membranes, but the rank
order of potency was similar, suggesting successful expres-
sion (Table 3). The lower apparent affinities of the ligands at
hD2 receptors in E. coli membranes may be attributed to
sticking of the compounds and/or [3H]spiperone (see Fig. 1, B
and C: high nonspecific binding of [3H]spiperone) to E. coli
membranes. Alternatively, it may be attributed to the differ-
ent composition of bacterial membranes; lower affinities of
antagonists have also been observed for dopamine D2 recep-
tors expressed in Saccharomyces cerevisiae (Sander et al.,
1994). Also, the different protein amount and assay volume
in the binding assays for hD2R-E. coli and -CHO membranes
may lead to the lower apparent affinities of the compounds in
E. coli membranes versus CHO membranes. Inhibition bind-
Fig. 2. Radioligand binding isotherms using [3H]7-OH-DPAT in the absence or presence of a Gi/o-protein mix (2.3 nM) at hD3-E. coli membranes (A)
and in the presence of a Gi/o-protein mix (2.3 nM) at hD2S-E. coli membranes (B). No specific [
3H]7-OH-DPAT binding to hD2S-E. coli membranes could
be detected in the absence of G-proteins. Experiments are performed as described under Experimental Procedures. Representative curves are shown
in which each point was determined in duplicate. [3H]7-OH-DPAT had an apparent binding affinity of 1.7 6 0.2 nM (n 5 4) for untreated (Bmax 5
2000 6 300 fmol/mg of protein) and 1.1 6 0.2 nM (n 5 4) for G-protein-treated hD3R-E. coli membranes (Bmax 5 2200 6 300 fmol/mg of protein).
[3H]7-OH-DPAT had an apparent binding affinity of 3.5 6 0.1 nM (n 5 2) (Bmax 5 160 6 30 fmol/mg of protein) for G-protein-treated hD2SR-E. coli
membranes.
280 Vanhauwe et al. Vol. 295
ing constants using [3H]7-OH-DPAT in membranes of
hD2SR- or hD2LR-expressing E. coli could not be determined
due to the absence of radioligand binding at nanomolar con-
centration. In CHO and E. coli cell membranes, compounds
had similar affinities for hD2S and hD2L receptors, respec-
tively. This confirms previous findings and expands the idea
of similar binding properties of these splice variants also to
the G-protein-free environment in E. coli membranes
(Schotte et al., 1996).
G-Protein Uncoupling Decreases High Affinity Ago-
nist Binding at hD2 Receptors. GppNHp treatment sig-
nificantly decreased the affinity of [3H]7-OH-DPAT at
hD2SR-CHO and hD2LR-CHO cell membranes (Table 1).
Moreover, the lack of [3H]7-OH-DPAT binding at nanomolar
concentration in hD2SR-E. coli and hD2LR-E. coli membranes
indicates that hD2 receptors have a low affinity for [
3H]7-OH-
DPAT in the total absence of G-proteins. Probably, G-pro-
teins in CHO membranes cannot be fully dissociated from
their receptor by GppNHp leading to an intermediate (“low”)
affinity for agonists. It was observed that [3H]7-OH-DPAT
bound to hD2SR-E. coli membranes in the presence of a
Gi/o-protein mix with an affinity similar to what was found in
hD2SR-CHO cell membranes, indicating proper folding of the
receptor and reconstitution of the high affinity state. This
reconstitution was reversible, because GppNHp treatment
abolished [3H]7-OH-DPAT binding. Furthermore, we found
significantly lower potencies (10–20-fold lower) of dopamine
and 7-OH-DPAT for inhibition of [3H]spiperone binding to
hD2SR- and hD2LR-E. coli membranes (Table 3), indicating
again that high affinity agonist binding to D2 receptors re-
quires the presence of G-proteins.
G-Protein-Coupled and Uncoupled States of hD3 Re-
ceptors Are Similar. It is generally assumed that D3 recep-
tors poorly couple to G-proteins or that the investigated cell
systems do not possess the suitable G-proteins to explain a
small (or no) shift in high affinity agonist binding on GTPgS
treatment. The latter assumption is further substantiated by
studies reporting the inability of D3 receptors to regulate
effector systems (Freedman et al., 1994; Tang et al., 1994).
However, in recent publications it was shown that D3 recep-
tors do activate G-proteins (Vanhauwe et al., 1999). How-
ever, it has not been established whether the slight modula-
tion of agonist binding by guanine nucleotides is due to a
particular interaction between the D3 receptor and its target
G-protein or that it is due to specific properties of the recep-
tor itself. Our results confirm that GppNHp treatment does
Fig. 3. Reconstitution of high affinity [3H]7-OH-DPAT binding at hD2S and hD3 receptors in E. coli membranes using a Gi/o-protein mix. Experiments
are performed as described under Experimental Procedures. Curves represent the mean of four experiments 6 S.D. Derived pEC50 values are 8.35 6
0.06 for hD3R-E. coli and 8.12 6 0.06 for hD2SR-E. coli. The same amount of protein (35 mg) and incubation volume (0.5 ml) was used for hD2SR-E.
coli and hD3R-E. coli membranes. The inset represents the increase of total bound [
3H]7-OH-DPAT as a function of the ratio of G-protein/receptor. The
arrows indicate the ratio G-protein/receptor that corresponds to what was used for generating the [3H]7-OH-DPAT saturation binding isotherms (see
Fig. 2). Binding equilibrium constants were calculated assuming expression levels (Bmax) of 2000 fmol/mg for hD3 receptors and 1000 fmol/mg for hD2S
receptors and with the equation: K 5 (Bmax 2 [DxRzG])[G])/[DxRzG] in which [DxRzG] is the concentration of the high affinity dopamine receptor-G-
protein complex (difference between binding in untreated and G-protein-mixed membranes) and [G] is the concentration of the exogenously added
G-protein mix. Kd values were calculated using the estimated concentrations of the reaction components at the level of the pEC50 values of the
G-protein mix. We found for the hD3RzGi/o-protein an apparent Kd of 1.4 3 10
27 M and for the hD2SRzGi/o-protein an apparent Kd of 9.4 3 10
28 M.
2000 Ligand Binding and G-Protein Interaction of hD2 and hD3 Receptors 281
not decrease the affinity of an agonist ([3H]7-OH-DPAT) for
hD3 receptors in CHO cell membranes. Most interestingly,
we found that [3H]7-OH-DPAT had similar affinities for hD3
receptors in E. coli and CHO cell membranes (Table 1). This
clearly shows that high affinity agonist binding to hD3 recep-
tor is almost independent of G-proteins, which makes it un-
likely that a tight association between receptor and G-protein
would prevent the effect of guanine nucleotides.
Inverse Agonists Do Not Have Higher Affinities for
Uncoupled hD2 and hD3 Receptors. It was hypothesized
that inverse agonists would have higher affinities for uncou-
pled than for coupled receptors (Costa et al., 1992). Antago-
nists tested in this study have been reported to be inverse
agonists at hD2S (haloperidol, domperidone, risperidone,
spiperone, and nemonapride) and hD3 receptors (haloperidol
and raclopride) (Griffon et al., 1996; Hall and Strange, 1997;
Kozell and Neve, 1997; Malmberg et al., 1998; Vanhauwe et
al., 2000). However, Malmberg et al. (1998) reported no shift
to higher affinities for inverse agonists at hD3 receptors after
pertussis toxin treatment of the membranes. Here, we dem-
onstrate that in E. coli membranes, which are devoid of
G-proteins, these presumed inverse agonists do not have
higher affinities for hD2S, hD2L, or hD3 receptors than in
CHO cell membranes. Therefore, the theory of the allosteric
ternary complex model with regard to inverse agonists seems
not to be generally applicable.
A Purified Bovine G-Protein Mix Has a Comparable
Affinity for hD3 and hD2 Receptors. It is not known why
D3 receptors activate G-proteins (much) less efficiently than
D2 receptors. Several hypotheses have been put forward,
such as inability to activate and/or couple to G-proteins,
unavailability of suitable G-proteins, or a low affinity toward
G-proteins. To address this issue, we have tried to estimate
the affinity of a subset of pertussis toxin-sensitive G-proteins
for the hD2S and hD3 receptors. Therefore, we have reconsti-
tuted high affinity [3H]7-OH-DPAT binding at hD2SR- and
hD3R-E. coli membranes by addition of increasing concentra-
tions of exogenous Gi/o-proteins, purified from bovine brain.
As was found before, no specific [3H]7-OH-DPAT binding was
detectable in the absence of G-proteins at hD2SR-E. coli
membranes, in contrast to hD3R-E. coli membranes. How-
ever, the G-protein mix increased [3H]7-OH-DPAT binding in
a dose-dependent manner at either receptor, whereas it had
no effect on antagonist binding (latter results not shown).
Most surprisingly, the G-protein mix was at least as potent
in increasing high affinity agonist binding at hD3 receptors
than at hD2S receptors. The estimated Kd of 1.4 3 10
27 M for
the hD3RzGi/o complex and the Kd of 9.4 3 10
28 M for the
hD2SRzGi/o complex corresponded to reported affinities of G-
proteins for G-protein-coupled receptors. In addition, the G-
protein/receptor ratio for half-maximal effect was similar to
previous findings for A1-adenosine and 5HT1A receptors in E.
coli membranes (Bertin et al., 1992; Jockers et al., 1994) and
slightly higher for dopamine D2S receptors in Sf9 membranes
(Gru¨newald et al., 1996). The G-protein/receptor ratio is
probably overestimated due to the presence of inactive, pu-
rified G-protein contaminations and/or nonoptimal insertion
of G-proteins in E. coli membranes. It cannot be concluded
that more G-proteins per receptor were required for recon-
stituting high affinity binding at hD3 receptors (versus hD2S
receptors), because more receptors were expressed in the
hD3-E. coli membranes. Therefore, a more efficient way was
to calculate the Kd values based on our results (see Fig. 3 and
legend), which showed that there was no difference in affinity
between hD2S and hD3 receptors for the Gi/o-protein mix.
Until recently, it was generally believed that hD3 receptors
couple poorly to G-proteins when compared with D2 recep-
tors. Now, we found an equally strong interaction of hD3
receptors compared with hD2 receptors with a Gi/o-protein
mix. Robinson and Caron (1996) suggested a weak interac-
tion between hD3 receptors and G-proteins due to a con-
strained receptor structure. We propose a strong interaction
between hD3 receptors and G-proteins, but a rigid receptor
structure that is little influenced by G-protein coupling. The
rigid hD3 receptor activates G-proteins less efficient than D2
receptors. Hence, the receptor-G-protein interaction can be
described by two independent parameters, analogous to the
agonist-receptor interaction, i.e., affinity and intrinsic activ-
ity. In this respect, hD3 receptors have a high affinity and a
low intrinsic activity at G-proteins, whereas hD2 receptors
have a high affinity and a high intrinsic activity at G-pro-
teins. In future studies, it will be interesting to define the
different regions of the receptor that contribute to either
G-protein coupling or activation.
In conclusion, we have expressed in E. coli hD2S, hD2L, and
hD3 receptors, which retained their antagonist binding prop-
erties. In E. coli, as well as in CHO cell membranes, agonist
binding to uncoupled receptors was severely impaired at
hD2S and hD2L receptors, whereas only a small effect was
observed at hD3 receptors. We found that the low and high
affinity states of hD3 receptors are similar, whereas for hD2S
and hD2L receptors they are clearly distinguishable. Further-
more, our results indicate that hD2S and hD3 receptors have
a similar affinity for an exogenously added Gi/o-protein mix.
Thus, the reported low signaling capacity of hD3 receptors, as
compared with hD2 receptors, is not due to a low affinity for
G-proteins but may be attributed to a constrained structure
of the receptor.
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